Investigating microRNAs as serum markers of elevated blood pressure.

Seodhna Lynch, Mary Ward, Helene McNulty, Geraldine Horigan, JJ Strain, John Purvis, Mike Tackett, Declan McKenna

Research output: Contribution to journalArticle

Abstract

Background: Cardiovascular disease (CVD) is the leading cause globally of morbidity and mortality. microRNAs (miRNAs) are small, non-coding RNAs which have a fundamental role in the pathology of various diseases including CVD. Circulating serum levels of miRNAs have been proposed as potentially valuable markers of heart failure, stroke, myocardial infarction and arterial hypertension, but the specific miRNAs involved and their function remains unclear. Therefore, this pilot study aims to profile miRNA expression in premature CVD patients to identify which miRNAs correlate best with hypertension.Methods: The Multiplex Circulating miRNA Assay with FireflyTM Particle Technologies was used to profile 68 miRNAs on a cardiology focus panel in serum samples from 170 premature CVD patients recruited from Altnagelvin Area Hospital and screened for the C677T polymorphism in methylenetetrahydrofolate reductase, a risk factor for hypertension. Samples were collected at baseline and following intervention with riboflavin, a co-factor for MTHFR, which significantly lowers blood pressure specifically in adults with this polymorphism. Statistical analysis was used to correlate miRNA expression with blood pressure, MTHFR genotype and other relevant clinical data.Results: The assay successfully measured miRNA expression in the sample set. miRNAs which expressed differentially between MTHFR genotype groups were highlighted and the functional significance of these miRNAs was assessed using bioinformatics to identify target genes involved in CVD.Conclusions: The data provides further evidence that using specific miRNAs as serum markers could aid early prediction of CVD and may lead to better diagnostic modalities and therapeutic regimes.
LanguageEnglish
Pages8-8
JournalUlster Medical Journal
Volume86
Issue number1
Publication statusPublished - 1 Jan 2017

Fingerprint

MicroRNAs
Biomarkers
Blood Pressure
Cardiovascular Diseases
Hypertension
Genotype
Small Untranslated RNA
Methylenetetrahydrofolate Reductase (NADPH2)
Riboflavin
Computational Biology
Cardiology
Serum
Heart Failure
Stroke
Myocardial Infarction
Pathology
Technology
Morbidity

Keywords

  • microRNAs
  • hypertension
  • Serum biomarker
  • MTHFR
  • Riboflavin
  • cardiovascular disease

Cite this

Lynch, Seodhna ; Ward, Mary ; McNulty, Helene ; Horigan, Geraldine ; Strain, JJ ; Purvis, John ; Tackett, Mike ; McKenna, Declan. / Investigating microRNAs as serum markers of elevated blood pressure. In: Ulster Medical Journal. 2017 ; Vol. 86, No. 1. pp. 8-8.
@article{6041a99b2d2f4d139be1494a55cd474c,
title = "Investigating microRNAs as serum markers of elevated blood pressure.",
abstract = "Background: Cardiovascular disease (CVD) is the leading cause globally of morbidity and mortality. microRNAs (miRNAs) are small, non-coding RNAs which have a fundamental role in the pathology of various diseases including CVD. Circulating serum levels of miRNAs have been proposed as potentially valuable markers of heart failure, stroke, myocardial infarction and arterial hypertension, but the specific miRNAs involved and their function remains unclear. Therefore, this pilot study aims to profile miRNA expression in premature CVD patients to identify which miRNAs correlate best with hypertension.Methods: The Multiplex Circulating miRNA Assay with FireflyTM Particle Technologies was used to profile 68 miRNAs on a cardiology focus panel in serum samples from 170 premature CVD patients recruited from Altnagelvin Area Hospital and screened for the C677T polymorphism in methylenetetrahydrofolate reductase, a risk factor for hypertension. Samples were collected at baseline and following intervention with riboflavin, a co-factor for MTHFR, which significantly lowers blood pressure specifically in adults with this polymorphism. Statistical analysis was used to correlate miRNA expression with blood pressure, MTHFR genotype and other relevant clinical data.Results: The assay successfully measured miRNA expression in the sample set. miRNAs which expressed differentially between MTHFR genotype groups were highlighted and the functional significance of these miRNAs was assessed using bioinformatics to identify target genes involved in CVD.Conclusions: The data provides further evidence that using specific miRNAs as serum markers could aid early prediction of CVD and may lead to better diagnostic modalities and therapeutic regimes.",
keywords = "microRNAs, hypertension, Serum biomarker, MTHFR, Riboflavin, cardiovascular disease",
author = "Seodhna Lynch and Mary Ward and Helene McNulty and Geraldine Horigan and JJ Strain and John Purvis and Mike Tackett and Declan McKenna",
year = "2017",
month = "1",
day = "1",
language = "English",
volume = "86",
pages = "8--8",
journal = "Ulster Medical Journal, The",
issn = "0041-6193",
number = "1",

}

Investigating microRNAs as serum markers of elevated blood pressure. / Lynch, Seodhna; Ward, Mary; McNulty, Helene; Horigan, Geraldine; Strain, JJ; Purvis, John; Tackett, Mike; McKenna, Declan.

In: Ulster Medical Journal, Vol. 86, No. 1, 01.01.2017, p. 8-8.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Investigating microRNAs as serum markers of elevated blood pressure.

AU - Lynch, Seodhna

AU - Ward, Mary

AU - McNulty, Helene

AU - Horigan, Geraldine

AU - Strain, JJ

AU - Purvis, John

AU - Tackett, Mike

AU - McKenna, Declan

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: Cardiovascular disease (CVD) is the leading cause globally of morbidity and mortality. microRNAs (miRNAs) are small, non-coding RNAs which have a fundamental role in the pathology of various diseases including CVD. Circulating serum levels of miRNAs have been proposed as potentially valuable markers of heart failure, stroke, myocardial infarction and arterial hypertension, but the specific miRNAs involved and their function remains unclear. Therefore, this pilot study aims to profile miRNA expression in premature CVD patients to identify which miRNAs correlate best with hypertension.Methods: The Multiplex Circulating miRNA Assay with FireflyTM Particle Technologies was used to profile 68 miRNAs on a cardiology focus panel in serum samples from 170 premature CVD patients recruited from Altnagelvin Area Hospital and screened for the C677T polymorphism in methylenetetrahydrofolate reductase, a risk factor for hypertension. Samples were collected at baseline and following intervention with riboflavin, a co-factor for MTHFR, which significantly lowers blood pressure specifically in adults with this polymorphism. Statistical analysis was used to correlate miRNA expression with blood pressure, MTHFR genotype and other relevant clinical data.Results: The assay successfully measured miRNA expression in the sample set. miRNAs which expressed differentially between MTHFR genotype groups were highlighted and the functional significance of these miRNAs was assessed using bioinformatics to identify target genes involved in CVD.Conclusions: The data provides further evidence that using specific miRNAs as serum markers could aid early prediction of CVD and may lead to better diagnostic modalities and therapeutic regimes.

AB - Background: Cardiovascular disease (CVD) is the leading cause globally of morbidity and mortality. microRNAs (miRNAs) are small, non-coding RNAs which have a fundamental role in the pathology of various diseases including CVD. Circulating serum levels of miRNAs have been proposed as potentially valuable markers of heart failure, stroke, myocardial infarction and arterial hypertension, but the specific miRNAs involved and their function remains unclear. Therefore, this pilot study aims to profile miRNA expression in premature CVD patients to identify which miRNAs correlate best with hypertension.Methods: The Multiplex Circulating miRNA Assay with FireflyTM Particle Technologies was used to profile 68 miRNAs on a cardiology focus panel in serum samples from 170 premature CVD patients recruited from Altnagelvin Area Hospital and screened for the C677T polymorphism in methylenetetrahydrofolate reductase, a risk factor for hypertension. Samples were collected at baseline and following intervention with riboflavin, a co-factor for MTHFR, which significantly lowers blood pressure specifically in adults with this polymorphism. Statistical analysis was used to correlate miRNA expression with blood pressure, MTHFR genotype and other relevant clinical data.Results: The assay successfully measured miRNA expression in the sample set. miRNAs which expressed differentially between MTHFR genotype groups were highlighted and the functional significance of these miRNAs was assessed using bioinformatics to identify target genes involved in CVD.Conclusions: The data provides further evidence that using specific miRNAs as serum markers could aid early prediction of CVD and may lead to better diagnostic modalities and therapeutic regimes.

KW - microRNAs

KW - hypertension

KW - Serum biomarker

KW - MTHFR

KW - Riboflavin

KW - cardiovascular disease

M3 - Article

VL - 86

SP - 8

EP - 8

JO - Ulster Medical Journal, The

T2 - Ulster Medical Journal, The

JF - Ulster Medical Journal, The

SN - 0041-6193

IS - 1

ER -